Inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ), a NF-kB activator, is overexpressed in CLL patients, resulting in exacerbated NF-kB signaling [33]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.